These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22939006)

  • 41. Behavioral and endocrine response to cholecystokinin tetrapeptide in patients with posttraumatic stress disorder.
    Kellner M; Wiedemann K; Yassouridis A; Levengood R; Guo LS; Holsboer F; Yehuda R
    Biol Psychiatry; 2000 Jan; 47(2):107-11. PubMed ID: 10664826
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased brain serotonin turnover in panic disorder patients in the absence of a panic attack: reduction by a selective serotonin reuptake inhibitor.
    Esler M; Lambert E; Alvarenga M; Socratous F; Richards J; Barton D; Pier C; Brenchley C; Dawood T; Hastings J; Guo L; Haikerwal D; Kaye D; Jennings G; Kalff V; Kelly M; Wiesner G; Lambert G
    Stress; 2007 Aug; 10(3):295-304. PubMed ID: 17613943
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder.
    Bradwejn J; Koszycki D; Annable L; Couëtoux du Tertre A; Reines S; Karkanias C
    Biol Psychiatry; 1992 Nov; 32(10):903-12. PubMed ID: 1467375
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy volunteers.
    Koszycki D; Cox BJ; Bradwejn J
    Am J Psychiatry; 1993 Dec; 150(12):1881-3. PubMed ID: 8238648
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Associations between personality traits and CCK-4-induced panic attacks in healthy volunteers.
    Tõru I; Aluoja A; Võhma U; Raag M; Vasar V; Maron E; Shlik J
    Psychiatry Res; 2010 Jul; 178(2):342-7. PubMed ID: 20471107
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Effect of Escitalopram on Central Serotonergic and Dopaminergic Systems in Patients with Cervical Dystonia, and Its Relationship with Clinical Treatment Effects: A Double-Blind Placebo-Controlled Trial.
    Zoons E; Tijssen MAJ; Dreissen YEM; Smit M; Booij J
    Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32521736
    [No Abstract]   [Full Text] [Related]  

  • 47. The acute antipanic activity of aerobic exercise.
    Ströhle A; Feller C; Onken M; Godemann F; Heinz A; Dimeo F
    Am J Psychiatry; 2005 Dec; 162(12):2376-8. PubMed ID: 16330604
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of the beta-noradrenergic system in cholecystokinin-tetrapeptide-induced panic symptoms.
    Le Mellédo JM; Bradwejn J; Koszycki D; Bichet DG; Bellavance F
    Biol Psychiatry; 1998 Sep; 44(5):364-6. PubMed ID: 9755359
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of citalopram and escitalopram on fMRI response to affective stimuli in healthy volunteers selected by serotonin transporter genotype.
    Henry ME; Lauriat TL; Lowen SB; Churchill JH; Hodgkinson CA; Goldman D; Renshaw PF
    Psychiatry Res; 2013 Sep; 213(3):217-24. PubMed ID: 23845563
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sensitivity to cholecystokinin-tetrapeptide in major depression.
    Koszycki D; Copen J; Bradwejn J
    J Affect Disord; 2004 Jun; 80(2-3):285-90. PubMed ID: 15207943
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study.
    Langley C; Armand S; Luo Q; Savulich G; Segerberg T; Søndergaard A; Pedersen EB; Svart N; Overgaard-Hansen O; Johansen A; Borgsted C; Cardinal RN; Robbins TW; Stenbæk DS; Knudsen GM; Sahakian BJ
    Neuropsychopharmacology; 2023 Mar; 48(4):664-670. PubMed ID: 36683090
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Functional magnetic resonance imaging characterization of CCK-4-induced panic attack and subsequent anticipatory anxiety.
    Schunck T; Erb G; Mathis A; Gilles C; Namer IJ; Hode Y; Demaziere A; Luthringer R; Macher JP
    Neuroimage; 2006 Jul; 31(3):1197-208. PubMed ID: 16600640
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo.
    Bandelow B; Stein DJ; Dolberg OT; Andersen HF; Baldwin DS
    Pharmacopsychiatry; 2007 Jul; 40(4):152-6. PubMed ID: 17694478
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CCK4-induced panic in healthy subjects I: psychological and cardiovascular effects.
    Jerabek I; Boulenger JP; Bradwejn J; Lavallée YJ; Jolicoeur FB
    Eur Neuropsychopharmacol; 1999 Jan; 9(1-2):149-55. PubMed ID: 10082241
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Experimental panic provocation in healthy man-a translational role in anti-panic drug development?
    Kellner M
    Dialogues Clin Neurosci; 2011; 13(4):485-93. PubMed ID: 22275853
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients.
    Bradwejn J; Koszycki D
    Am J Psychiatry; 1994 Feb; 151(2):261-3. PubMed ID: 8296900
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder.
    Ströhle A; Holsboer F; Rupprecht R
    Neuropsychopharmacology; 2000 Mar; 22(3):251-6. PubMed ID: 10693152
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CCK-4-induced anxiety but not panic is associated with serum brain-derived neurotrophic factor in healthy subjects.
    Maron E; Tõru I; Mäemets K; Sepp S; Vasar V; Shlik J; Zharkovsky A
    J Psychopharmacol; 2009 Jun; 23(4):460-4. PubMed ID: 18562429
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of repetitive transcranial magnetic stimulation (rTMS) on panic attacks induced by cholecystokinin-tetrapeptide (CCK-4).
    Zwanzger P; Eser D; Völkel N; Baghai TC; Möller HJ; Rupprecht R; Padberg F
    Int J Neuropsychopharmacol; 2007 Apr; 10(2):285-9. PubMed ID: 16817979
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder.
    Kramer MS; Cutler NR; Ballenger JC; Patterson WM; Mendels J; Chenault A; Shrivastava R; Matzura-Wolfe D; Lines C; Reines S
    Biol Psychiatry; 1995 Apr; 37(7):462-6. PubMed ID: 7786960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.